Biomarkers of drug-induced acute kidney injury in the adult

Gobe, Glenda C., Coombes, Jeff S., Fassett, Robert G. and Endre, Zoltan H. (2015) Biomarkers of drug-induced acute kidney injury in the adult. Expert Opinion on Drug Metabolism and Toxicology, 11 11: 1683-1694. doi:10.1517/17425255.2015.1083011

Author Gobe, Glenda C.
Coombes, Jeff S.
Fassett, Robert G.
Endre, Zoltan H.
Title Biomarkers of drug-induced acute kidney injury in the adult
Journal name Expert Opinion on Drug Metabolism and Toxicology   Check publisher's open access policy
ISSN 1744-7607
Publication date 2015-11-02
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1517/17425255.2015.1083011
Open Access Status Not Open Access
Volume 11
Issue 11
Start page 1683
End page 1694
Total pages 12
Place of publication Abingdon, United Kingdom
Publisher Taylor and Francis
Collection year 2016
Language eng
Formatted abstract
Introduction: This article addresses general biomarkers of drug-induced acute kidney injury (AKI) and their application in development and progression of AKI in the adult. It also highlights some clinical benefits, but also uncertainties, of biomarker use.

Areas covered: Drug-induced AKI is traditionally diagnosed by monitoring serum creatinine (SCr), blood urea nitrogen and albuminuria. The sensitivity of these measures is, however, limited to well-established AKI. Application of selected biomarkers for early diagnosis of drug-induced AKI may inform on progression of AKI and alert clinicians to adopt renoprotective strategies at the earliest times. Novel biomarkers, accepted for early detection of drug-induced AKI (kidney injury molecule-1, neutrophil gelatinase-associated lipocalin and N-acetyl-β-d-glucosaminidase), may be useful additions in panels of biomarkers. Clinical biomarkers of cell cycle arrest, tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 show promise but need further validation in clinical trials.

Expert opinion: Traditional parameters, such as SCr, provide some guidance for functional decline in drug-induced AKI but early, more sensitive, affordable, clinically acceptable, biomarkers of kidney dysfunction are needed. Basic biological understanding of AKI will improve with high-throughput methodologies such as proteomics and metabolomics, and this should lead to identification and usage of novel biomarkers. Ultimately, a combination of biomarkers indicating kidney dysfunction and damage is likely to be required.
Keyword Acute kidney injury
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2016 Collection
School of Human Movement and Nutrition Sciences Publications
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 24 Nov 2015, 02:21:37 EST by System User on behalf of Scholarly Communication and Digitisation Service